Related Experiment Videos
Pulmonary disease due to antirheumatic agents
1Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.
Clinics in Chest Medicine
|March 11, 1990
Summary
Drug-induced lung disease from antirheumatic agents is hard to diagnose and treat. Identifying the specific drug causing lung damage is challenging due to multiple medications and lack of markers.
Area of Science:
- Pulmonology
- Rheumatology
- Clinical Pharmacology
Background:
- Drug-induced lung disease (DILD) poses diagnostic and therapeutic challenges.
- DILD associated with antirheumatic agents is complex, as pulmonary symptoms may stem from the underlying condition.
- Lack of specific biomarkers complicates differentiating DILD from other lung pathologies.
Purpose of the Study:
- To review pulmonary damage associated with six classes of anti-inflammatory/antirheumatic agents.
- To discuss the clinical syndromes and management strategies for DILD in rheumatic disorders.
Main Methods:
- Literature review of drug-induced lung disease.
- Focused analysis on six drug classes: penicillamine, gold, methotrexate, salicylates, NSAIDs, and colchicine.
- Categorization of associated pulmonary syndromes.
Main Results:
- Six drug classes linked to pulmonary damage: penicillamine, gold, methotrexate, NSAIDs, salicylates, and colchicine.
- Identified syndromes include hypersensitivity pneumonitis, chronic alveolitis/fibrosis, pulmonary-renal syndrome, bronchiolitis obliterans, and pulmonary edema.
- Treatment primarily involves drug withdrawal and supportive care; corticosteroids for severe cases.
Conclusions:
- Differentiating drug-induced lung disease from other conditions is difficult.
- Limited treatment options exist, with drug cessation and supportive care being primary.
- Corticosteroids and immunosuppressants may be used in severe or refractory cases, based on limited evidence.